Jihao Zhou

Dr. Zhou is vice president of clinical development at Autobahn Therapeutics.

Dr. Zhou is an accomplished clinical development executive with 20 years of experience and a track record of NDA/BLA filings with approval in oncology, neuroscience, urology, and ophthalmology. Before joining Autobahn, he served as vice president and head of data sciences at AnaptysBio. Prior to that, Dr. Zhou was the senior medical director in clinical development at Urovant Sciences, where he was responsible for the clinical development of GEMTESA® (vibegron) for the treatment of overactive bladder (OAB) and led OAB-BPH Phase 3 program. Dr. Zhou was employed at Allergan from 2005 to 2018, serving in leadership roles of increasing responsibilities. During his tenure at Allergan, Dr. Zhou and his team supported the development of multiple products and/or indications, including Botox® indicated for the treatment of upper limb (post-stroke) spasticity, Botox® for neurogenic detrusor overactivity, Botox® for OAB, Noctiva® for the treatment of nocturnal polyuria, and Refresh Tears® eye drops for the treatment of dry eye. Earlier at Pfizer, Dr. Zhou was part of the oncology development team responsible for submission and approval of Sutent® (sunitinib) for metastatic renal cell carcinoma and gastrointestinal stromal cancer. Dr. Zhou is an inventor or co-inventor of patents and patent applications in multiple therapeutic areas such as ophthalmology, gastroenterology, urology, and cardiology. Dr. Zhou received his M.D. from Peking Union Medical College and his Ph.D. in biostatistics from the University of Michigan, Ann Arbor, and completed his post-doctoral fellowship in cardiology/ arteriosclerosis at the University of Münster.